Perimenopause Symptom Map

Healthcare · §646

Perimenopause is the multi-year stretch — usually four years, sometimes ten — between regular cycles and the final period, and it produces a coordinated symptom pattern most women never see named in one place. Cycle length starts wobbling. Sleep breaks. Mood gets less stable. Memory and word-finding dip slightly. Hot flashes start, and then keep going for years, often well past the final period. The reason none of these get connected is that they don't arrive on the same day; they roll out one at a time over a decade, and each one gets handed a separate explanation.

Know · Once Evidence Strong Chapter Healthcare

The win here is recognition itself. Naming the pattern collapses six separate worries — am I sick, am I losing it, why can't I sleep, why am I crying — into one explainable transition with a known shape and a known endpoint. Recognition is the gate; almost every part of the symptom map has a real treatment behind it, but only if you and your doctor are looking at the right problem. None of this is exotic or hard; the catch is that the pieces are spread across years, so the connection has to be made by you.

The engine underneath all of it is that the ovaries are running out of eggs. The follicle pool has been shrinking since birth; by the early 40s there are few enough left that the back-and-forth between brain and ovary can't keep cycles regular anymore. The counter-intuitive part: estrogen doesn't quietly fall. It swings. Some cycles spike well above what it used to be, then crash. Other cycles barely produce any. The brain reads each crash as a withdrawal — and that withdrawal is what triggers most of the symptoms Santoro 2021.

This is why a single blood test can't tell you where you are. The hormone the doctor will order — FSH — bounces around inside a single cycle, never mind across cycles. The international staging system (STRAW+10) deliberately stages perimenopause by what your periods are doing, not what the lab says, because bleeding patterns are more honest than a hormone snapshot Harlow et al. 2012.

The six symptom domains, mapped

The pattern below is what the longest-running study of midlife women, the Study of Women's Health Across the Nation (SWAN), has been documenting in roughly 3,300 women followed since the mid-90s El Khoudary et al. 2016. Each domain rolls in at a slightly different stage; together they make the shape.

Cycles

The first sign in most women isn't fewer periods — it's shorter cycles. The luteal phase contracts, so a 28-day cycle becomes a 24-day cycle. Then the variation widens: a 24, a 35, a 22, a missed one. Flow shifts too — some months become heavy and clotty, others light. STRAW+10 calls "cycles differing by 7+ days from your own normal" the official start of the early stage; an interval of 60+ days without a period is the late stage Harlow et al. 2012. The heavy, clotty months aren't just to be endured, either — while you're still cycling, hormonal contraception (not hormone therapy) is often the tool that smooths erratic and heavy bleeding alike.

Hot flashes and night sweats

Roughly 75 to 80% of women get them. The headline number from SWAN is the one most guides bury: the median total duration of hot flashes is 7.4 years, and the median time they persist after the final period is 4.5 years Avis et al. 2015. About a third of women are still flushing 10+ years after the final period Freeman et al. 2014. Duration varies sharply by background — African American women average around 10 years; Japanese and Chinese American women around 5 Avis et al. 2015.

Sleep

The sleep break is partly the night sweats waking you up, partly direct — the hormones that fall in the transition also help regulate sleep architecture, so even women without big night sweats often sleep lighter and wake more often Kravitz et al. 2008. A second thing happens that gets missed: rates of obstructive sleep apnea climb after the transition, partly from fat redistribution and partly because progesterone (which helps keep the upper airway open in sleep) drops away Park et al. 2020. New snoring or daytime sleepiness in a 50-year-old woman is worth taking seriously.

Mood

Risk of a new depressive episode roughly doubles compared to premenopause — and this holds after researchers control for life stress and prior depression history. The risk concentrates in the late stage, the year or two before the final period Bromberger et al. 2011. Anxiety and irritability follow a similar pattern. The mechanism appears to be the swings, not the floor: women whose estrogen levels move around more are the ones who get the mood symptoms, regardless of where their average sits Joffe et al. 2020.

Brain fog

The cognitive dip is real and small. SWAN's cognitive substudy tracked verbal memory and processing speed across the transition and found a measurable drop — on the order of one or two tenths of a standard deviation, which is just enough to notice in your own life and not enough to fail any normal test Greendale et al. 2009. The reassuring part: in the same data, the dip recovers after the transition is done. Whatever the transition is doing to memory and processing speed, it's a state, not damage.

Body composition

Lean mass starts dropping faster — about 0.2 kg per year, accelerating around the final period — and the fat that's left redistributes from hips and thighs to the abdomen. The waist gets thicker even when the scale doesn't move much. Bone is the silent one: trabecular bone loss roughly doubles in a defined window, from about 12 months before through about 24 months after the final period, and density lost here is hard to put back later Greendale et al. 2019 Matheson et al. 2003.

What most guides get wrong

"Perimenopause is when your periods stop." The opposite. The transition starts with cycle changes — shorter, longer, heavier, lighter, occasionally skipped — and the long stretches of no bleeding only show up in the late stage. By the time periods stop fully you're at the end of the transition, not the beginning Harlow et al. 2012.

"Hot flashes mean you're almost done." No. They typically last for years on either side of the final period — about 7.4 years total in the median, often persisting 5 years past the last bleed, sometimes longer than a decade Avis et al. 2015.

"A blood test will confirm it." The hormone the doctor will run, FSH, swings around within a single cycle and across cycles in the transition. A normal value mid-cycle doesn't rule perimenopause out; a high value before the transition doesn't rule it in. The international staging system uses bleeding pattern, not bloodwork, for exactly this reason Harlow et al. 2012.

"Mood changes are just midlife stress, not hormones." The doubled depression risk holds after controlling for life stress and prior depression. The hormonal swings are a separate, independent contributor Bromberger et al. 2011.

"Brain fog means dementia is starting." The dip is real, small, and recovers postmenopause in longitudinal data Greendale et al. 2009. New short-term memory blanks at 47 are far more likely to be the transition than anything sinister.

Where recognition goes wrong

Two failure modes, opposite directions.

Missing it. A woman in her early 40s, still getting periods, shows up at primary care with insomnia, anxiety, and trouble finding words. She gets worked up for thyroid disease (negative), screened for depression (handed an SSRI), and told to manage stress. None of those are wrong on their own; what's missing is the question "is this the start of the transition?" Cognitive symptoms in this window get pathologised as early dementia. Sleep problems get blamed on stress or sleep hygiene when the actual driver is night sweats she hasn't noticed yet, or new-onset sleep apnea Park et al. 2020.

Over-attributing. The opposite mistake — assuming everything in a 45-year-old's body is hormonal — misses real thyroid disease, iron deficiency, sleep apnea, primary depression, and the rest. The midlife window is exactly when several other slow-onset conditions also show up. Perimenopause is the default explanation to check, not the default explanation to conclude.

The third trap is the FSH test. A normal mid-cycle value gets read as "not perimenopause yet" and the conversation ends. The right answer is to ignore the single FSH value and ask about the bleeding pattern over the last year — which is exactly why tracking your cycle is worth more in this window than any blood draw Harlow et al. 2012.

Who experiences this differently

The central numbers — four-year transition, 7-ish years of hot flashes, doubled depression risk, small cognitive dip — are medians. The spread around them tracks a few variables worth knowing about.

Background. African American women report the longest hot-flash duration (around 10 years) and higher overall symptom burden. Japanese and Chinese American women report the shortest (around 5 years) and lower burden Avis et al. 2015.
BMI. Higher body weight is associated with more hot flashes in the transition itself (the older "extra weight protects you" idea was a postmenopausal artifact) Maslow & Boggs 2018.
Smoking. Smokers finish the transition about 1 to 2 years earlier and tend to have more hot flashes along the way Santoro 2021.
Prior reproductive mood history. Women with a history of bad PMS, postpartum depression, or hormonal-contraceptive-triggered mood changes have higher risk of depressive episodes in this transition. The same hormone-sensitive wiring is what's being challenged Maki et al. 2019.
Surgical menopause. Having both ovaries removed before the natural transition is a sudden, total estrogen drop, not a gradual transition. The symptoms tend to be more intense and the bone-loss curve steeper. It looks similar from the outside but isn't the same biology Stuenkel et al. 2015.

What happens if you don't catch it

Anchor: you are the typical reader — late 40s, periods still coming but not on the old schedule, occasionally waking at 3am, occasionally snapping at people you love, occasionally blanking on a word. Nothing dramatic. You assume it's stress, or work, or the kids. You don't bring it up at the doctor because each piece sounds too small to mention.

Year one. Sleep is fragmented enough that your usual morning sharpness is gone. You're drinking more coffee. The mood thing stays at "I'm just tired and irritable lately." Your partner notices that you're shorter-tempered; you notice you're crying at things that didn't used to make you cry. Hot flashes have started showing up at night and you call them "warm spells."

Year three. Hot flashes are happening at work and you're rearranging meetings to be near a window. The sleep is now a stable problem — you've started taking something over the counter most nights. Your doctor offers an SSRI for what looks like new-onset depression, and it helps a little but doesn't really fix it because the underlying driver isn't a primary depression Maki et al. 2019. You've put on weight in the middle that didn't used to live there. Sex hurts in a way it didn't used to and you've started avoiding it; you haven't told your doctor because there's no good moment to Portman & Gass 2014.

Year seven. Periods finally stopped two years ago. You assumed the symptoms would stop too. They didn't — the SWAN data says they typically continue for about 4.5 more years after the final period, and yours are tracking that Avis et al. 2015. The body-composition shift is now permanent-looking. A bone density scan, if anyone orders one, shows you lost significant density in the window around your final period — the highest-loss window — and you weren't being looked after in that window Matheson et al. 2003. The cardiovascular risk markers — LDL up, waist up, fasting glucose drifting — are doing what the post-transition trajectory does when no one is steering it El Khoudary et al. 2016.

None of that is dramatic in any single year. It's the accumulation, in a window where almost every piece had a real treatment available, that's the stake.

What changes when you catch it

Recognition itself is the first half of the payoff. The day you realise this is a known transition with a known shape, six separate worries collapse into one explainable thing. The brain fog isn't dementia. The crying isn't "I've become someone unstable." The sleep is broken for a reason and the reason has a name.

Within weeks of acting on it. If hot flashes and sleep are the loudest symptoms, the treatments that work for them — hormone therapy in suitable candidates, or non-hormonal options if not — typically cut hot-flash frequency by around three-quarters and restore the night NAMS 2022 Stuenkel et al. 2015. Local vaginal estrogen (essentially no systemic absorption, safe for most women including many breast cancer survivors) treats the painful-sex and recurrent UTI problem more or less completely Portman & Gass 2014.

Within months. If depression is the loudest symptom, the perimenopausal-depression guideline points at treatments — sometimes antidepressants, sometimes estrogen, sometimes both, sometimes CBT — that have specific evidence in this window. The response rate when the episode is recognised as transition-linked is meaningfully better than when it's treated as a generic depression Maki et al. 2019. The cognitive dip lifts naturally as the transition completes Greendale et al. 2009 — the payoff of recognising it is mostly about not panicking through the dip.

Over years. Catching the bone-loss window — the 12 months before through 24 months after the final period — earns you a baseline scan and a preservation plan in the window that matters most, instead of finding out about the density loss when something breaks at 65 Matheson et al. 2003. Acting on cardiovascular markers in the early-transition window appears to be more useful than acting on them a decade later — the timing matters in ways the literature has spent twenty years working out NAMS 2022.

The honest version: not every symptom resolves to baseline, and people experience the transition with very different intensities. But the version of you who has been told the symptoms are stress, and the version of you who knows what they are, end up in very different places by year five.

This entry is about recognising the transition. The treatments and screenings the symptom map points at live in their own entries — menopausal hormone therapy (formulations, candidate selection, the timing-hypothesis window), bone density screening in midlife, evaluating new sleep problems for sleep apnea, and the genitourinary syndrome of menopause as a treatable condition on its own. Menopause before age 40 (premature ovarian insufficiency) is a separate clinical entity with its own management.

Related in the handbook

Helps

— Most pieces of the symptom map have a treatment, and hormone therapy is the central one for the worst of them.
— Before menopause proper, hormonal contraception — not HRT — is often the tool that smooths the erratic bleeding and symptoms of the transition.

— Vaginal dryness and recurrent UTIs are part of the same transition — they just show up later than hot flashes.
— As estrogen falls through this transition, cardiovascular risk climbs — the symptom years are when the heart clock starts ticking faster.
— Cycles don't just lengthen in perimenopause — they can turn heavy, which is treatable, not just endured.
— The perimenopause transition shows up first as changing cycle length; a daily log catches it before symptoms make sense.
— Migraines often shift or worsen during perimenopause as hormones swing — it's part of the pattern.
— Bone loss speeds up sharply in this transition — a silent part of the map worth getting a baseline scan for.
— Mood crashes that were cyclical can intensify in perimenopause; if they track the cycle, PMDD may be part of the picture.
— Falling estrogen raises sleep apnea risk, and it's badly under-diagnosed in women — sometimes the real reason sleep falls apart here.
— Many perimenopause symptoms mimic an underactive thyroid; a TSH rules the thyroid in or out before you blame the transition.
— Heavier, more erratic bleeding in your forties can be a fibroid waking up in the hormone swings, not just the transition itself.

Substance and claimed effects

Perimenopause is the multi-year transition from regular ovulatory cycles to the final menstrual period (FMP) and the 12 months that follow it. The STRAW+10 staging system formalises it as two stages — early menopausal transition (cycle length differing by ≥7 days from personal normal, recurrent within 10 cycles) and late menopausal transition (an interval of amenorrhea ≥60 days) — driven by accelerating depletion of the ovarian follicle pool and increasingly erratic estradiol with rising FSH Harlow et al. 2012. Median duration is approximately 4 years, with substantial individual variability (range 1–10+ years); typical age at FMP in the United States is 51–52 Santoro et al. 2021. The transition produces a coordinated symptom pattern across six domains tracked in this entry: menstrual cycle changes, vasomotor symptoms (hot flashes, night sweats), sleep disruption, mood changes (depression risk roughly doubles), cognitive changes (verbal memory and processing speed dips), and body composition shifts (central adiposity, lean mass loss). The entry is scoped as a literacy / recognition entry (action: know) — naming what the transition is, what it does, and how its symptom pattern reads in real time. Downstream treatment entries (menopausal hormone therapy, non-hormonal vasomotor pharmacotherapy, sleep apnea evaluation in midlife women) are not in scope here; they belong in their own entries.

Evidence by addressing question

Mechanism

The underlying physiology is ovarian follicular depletion. Across reproductive life the antral follicle count declines roughly log-linearly; by the early 40s the pool is small enough that the hypothalamic-pituitary-ovarian axis can no longer maintain stable cyclic estradiol production Harlow et al. 2012. Two physiological hallmarks distinguish perimenopause from later reproductive aging: (1) estradiol becomes more variable rather than uniformly low — peak follicular-phase estradiol is often higher than premenopausal values for years before declining, producing wide swings within and across cycles; (2) FSH rises in response to falling inhibin B, but remains variable rather than monotonically elevated until late perimenopause Santoro et al. 2021. This variability — not pure deficiency — is the mechanism that ties the symptom map together. Vasomotor symptoms appear to track estradiol withdrawal episodes rather than absolute levels (the central thermoregulatory window narrows as estrogen falls, so small body-temperature elevations trigger flushing) Maslow & Boggs 2018. Mood vulnerability tracks the magnitude of estradiol fluctuation rather than its mean, with progesterone withdrawal contributing in late luteal phases Joffe et al. 2020. Sleep fragmentation is partly direct (hot flashes wake the sleeper) and partly indirect (estrogen modulates GABA and serotonin signalling in sleep-regulatory nuclei) Kravitz et al. 2008. Cognitive symptoms appear to reflect the transition itself — verbal memory transiently dips during perimenopause and recovers in postmenopause in longitudinal data, consistent with a state effect of estradiol fluctuation rather than permanent damage Greendale et al. 2009.

Evidence

The symptom map is anchored by the Study of Women's Health Across the Nation (SWAN), a 25+ year multi-ethnic longitudinal cohort of ~3,300 women followed from premenopause through postmenopause. SWAN established the duration, prevalence, and ethnic patterning of vasomotor symptoms: median total VMS duration is 7.4 years, with median post-FMP persistence of 4.5 years Avis et al. 2015. Approximately 75–80% of women experience VMS at some point in the transition; African American women have the longest median duration (~10.1 years), Japanese and Chinese American women the shortest (~4.8–5.4 years) Avis et al. 2015. The Penn Ovarian Aging Study independently replicated long VMS duration in a separate cohort Freeman et al. 2014. SWAN data also documented the depression-risk elevation: women with no prior depression history have approximately 2–4× increased odds of a new depressive episode during perimenopause compared to premenopause, with risk concentrated in the late perimenopausal stage Bromberger et al. 2011. The cognitive dip — small but consistent decrements in verbal memory and processing speed — was documented in the SWAN cognitive substudy across ~2,300 women, with effect sizes typically 0.1–0.2 standard deviations and recovery in postmenopause Greendale et al. 2009. Body composition trajectories were quantified in SWAN's DXA substudy: lean mass declines ~0.2 kg/year accelerating around the FMP, fat mass increases especially centrally, and the rate of bone loss roughly doubles in the 12 months before through 24 months after FMP Greendale et al. 2019 Matheson et al. 2003. The El Khoudary SWAN progress report integrates these findings into the cardiovascular and metabolic trajectory, including unfavourable LDL/HDL shifts and increased visceral adiposity over the transition El Khoudary et al. 2016. Clinical practice guidelines summarising the evidence — Endocrine Society Stuenkel et al. 2015, NAMS 2022 position statement NAMS 2022, and the perimenopausal depression guideline Maki et al. 2019 — all converge on the same symptom map and the same broad treatment framework.

Misconceptions

Three recurring misconceptions distort symptom recognition. (1) "Perimenopause is when your periods stop." The transition begins with cycle changes (shorter cycles initially as the luteal phase contracts, then increasingly variable intervals), not amenorrhea — amenorrhea defines the late stage. Median time from first cycle irregularity to FMP is ~4 years Harlow et al. 2012. (2) "Hot flashes mean it's almost over." SWAN data flip this: hot flashes typically persist a median of 4.5 years after the FMP, with one-third of women symptomatic 10+ years post-FMP Avis et al. 2015. (3) "Mood symptoms in midlife are situational, not hormonal." The doubled depression risk in the transition is observed after controlling for life-stress measures and prior depression history; the hormone-fluctuation contribution is independent Bromberger et al. 2011. A fourth, weaker misconception: that an FSH blood test can confirm perimenopause. Because FSH is highly variable within and between cycles in the transition, a single elevated value can occur premenopausally and a single normal value can occur in late perimenopause; STRAW+10 deliberately bases staging on bleeding pattern rather than FSH for this reason Harlow et al. 2012.

Audience and population variability

Audience is anatomically female; the entry's primary readership is ages 40–59, with onset in the late 30s for a minority and persistence into the 60s for some. Symptom prevalence and duration vary substantially by demographic and baseline factors. Race/ethnicity: African American women report longer VMS duration and higher symptom burden; East Asian American women shorter and lower Avis et al. 2015. Body composition: higher BMI is associated with more VMS in the perimenopausal stage (the older "obesity protects" framing was a postmenopausal artifact) Maslow & Boggs 2018. Prior reproductive history: women with prior premenstrual mood disorders or postpartum depression have higher risk of perimenopausal depressive episodes Maki et al. 2019. Surgical and induced menopause: bilateral oophorectomy before natural FMP produces an acute estrogen-withdrawal syndrome with more severe VMS and accelerated bone loss, and is sometimes confused with natural perimenopause but follows a different trajectory Stuenkel et al. 2015. Smoking: associated with earlier FMP (~1–2 years) and higher VMS burden Santoro et al. 2021.

Failure modes

The most common failure of recognition is symptom mis-attribution. A woman in early perimenopause with new-onset insomnia, anxiety, and brain fog presenting to primary care is frequently worked up for thyroid dysfunction, primary depression, or "stress" without the menopause transition being raised — particularly when she is in her early 40s and still cycling. Cognitive symptoms get pathologised as early dementia rather than recognised as the SWAN-documented transient transition effect Greendale et al. 2009. Sleep symptoms get attributed to sleep hygiene or stress when the underlying mechanism is nocturnal VMS or increased obstructive sleep apnea risk (OSA prevalence rises post-FMP, partly via fat redistribution and partly via loss of progesterone's upper-airway tone) Park et al. 2020. The second failure mode is over-attribution: assuming every symptom in a 45-year-old is perimenopause when an actual primary cause (thyroid disease, sleep apnea, iron deficiency, depression unrelated to hormonal fluctuation) is present. The third is the FSH test trap — clinicians or patients order serum FSH, get a normal value mid-cycle, and conclude perimenopause has been ruled out Harlow et al. 2012. The fourth is conflating perimenopause with menopause: treatment-decision thinking that defers all action until the FMP misses the highest-symptom window (late perimenopause) and the bone-loss acceleration window (12 months pre-FMP through 24 months post-FMP) Greendale et al. 2019 Matheson et al. 2003.

Stakes

The stakes of un-recognized perimenopause are concrete and tractable. Untreated vasomotor symptoms persist a median of 7.4 years, with attendant sleep fragmentation, daytime fatigue, and emerging evidence of cardiovascular signal: frequent or persistent hot flashes are associated with greater carotid intima-media thickness and adverse subclinical cardiovascular markers in SWAN Thurston et al. 2016. The depression-risk window is most pronounced in late perimenopause and resolves in postmenopause in most women, but a missed episode in this window often becomes a chronic recurrent depression that outlasts the transition Maki et al. 2019. Bone loss is the highest-stakes silent consequence: trabecular bone loss accelerates to ~2× the premenopausal rate in the late perimenopause / early postmenopause window, and bone density lost in this window is harder to restore later Matheson et al. 2003. Genitourinary syndrome of menopause (vaginal dryness, dyspareunia, recurrent UTI, urinary urgency) is progressive and does not spontaneously remit; without recognition it produces a slow erosion of sexual function and urinary continence over years Portman & Gass 2014.

Payoff

Recognition itself produces immediate reduction in alarm and self-mis-attribution (brain fog is not early dementia; mood instability is not "I've become someone unstable"; cycle chaos is not a missed cancer). It opens the door to evidence-based treatment of each symptom domain: menopausal hormone therapy for vasomotor and genitourinary symptoms in appropriate candidates within the timing-hypothesis window (within ~10 years of FMP, before age 60) NAMS 2022 Manson et al. 2017; non-hormonal VMS pharmacotherapy (SSRIs, gabapentin, fezolinetant) for women with contraindications Stuenkel et al. 2015; CBT and antidepressants for perimenopausal depression with stronger evidence than in premenopausal depression Maki et al. 2019; vaginal estrogen (essentially no systemic absorption, safe even in many breast cancer survivors) for GSM Portman & Gass 2014; baseline DXA and bone-density preservation planning in the high-loss window Matheson et al. 2003. The timing-hypothesis literature suggests cardiovascular and possibly cognitive benefits of MHT initiated early in the transition that are not present when initiated >10 years post-FMP NAMS 2022.

Out-of-scope

Not covered in this entry but adjacent: the protocol-level detail of menopausal hormone therapy (formulations, routes, dosing, candidate selection) belongs in a dedicated MHT entry; the bone-density screening protocol (DXA cadence, T-score thresholds, FRAX) belongs in a screening entry; sleep apnea evaluation in midlife women belongs in the apnea entry; the genitourinary syndrome of menopause as a specific treatable condition belongs in its own entry. Premature ovarian insufficiency (POI; menopause before age 40) is a distinct clinical entity with different management and is out of scope.

The credibility range

Optimist case

The symptom map is settled science. STRAW+10 staging is the international standard and is reproducible across cohorts Harlow et al. 2012. SWAN provides 25+ years of longitudinal data documenting the prevalence, duration, and ethnic patterning of each symptom domain El Khoudary et al. 2016. Treatment of the recognised symptoms is high-evidence: MHT reduces VMS by ~75% in RCTs and treats GSM completely NAMS 2022; the perimenopausal depression guideline is built on multiple replicated trials Maki et al. 2019. The literacy intervention this entry represents is highly leveraged: a single 10-minute read can shift years of trajectory by getting the reader to the right diagnostic question.

Skeptic case

Symptom-attribution to perimenopause has expanded faster than the evidence in popular media. Many "perimenopause" symptoms — fatigue, weight gain, brain fog, low libido, joint aches — also have base rates that rise in midlife independent of hormonal transition, and longitudinal studies have variable success isolating the transition's contribution from aging-per-se. The cognitive dip is statistically real but small (effect sizes 0.1–0.2 SD) and recovers postmenopausally Greendale et al. 2009; popular framing as "brain fog that lasts forever" is not what SWAN actually shows. Treatment benefits — particularly MHT's cardiovascular and cognitive effects — remain contested between the WHI generation of trials and the timing-hypothesis re-analyses; the field is closer to consensus on safety in the early-transition window than on benefit for indications other than VMS and GSM Manson et al. 2017. Body-composition and bone-loss changes are partly attributable to chronological aging and are not exclusively a transition phenomenon, though SWAN does isolate a transition-specific acceleration Greendale et al. 2019.

Author's call

The core symptom map — vasomotor, sleep, mood, cognition, cycle, body composition, GSM, bone — is well-evidenced, replicated across cohorts, and not seriously contested. Quantitative claims in this entry stay close to SWAN-documented numbers (median VMS duration 7.4 years, ~2× depression risk, small cognitive dip with recovery). The entry is conservative on which symptoms are causally attributable to the transition versus midlife co-occurring, and conservative on downstream treatment specifics (which are scoped to other entries). evidence rates a 5 (multiple large longitudinal cohorts plus replicated guidelines). controversy rates 2 — the symptom map itself is non-controversial; MHT use is contested but is not the substance of this entry.

Stakeholder and incentive map

Pushing the topic: NAMS and the broader menopause-specialist clinical community (legitimate; pushing for under-recognized condition awareness); a growing online "perimenopause influencer" sector and direct-to-consumer telehealth (mixed incentives; many are useful but some over-attribute and over-prescribe); pharmaceutical interests in MHT and newer non-hormonal VMS drugs (fezolinetant launch 2023). Pushing back: a generation of clinicians trained during the post-WHI MHT pullback who under-treat menopausal symptoms; primary care time pressure that makes hormonal symptom workup less attractive than handing out an SSRI; lingering cultural framing of menopause as "natural, just endure it." The reader needs to be aware that both over- and under-attribution failure modes exist.

Population variability

See "Audience and population variability" subsection above. Key variables: race/ethnicity (substantial VMS-duration differences), BMI, smoking, prior reproductive psychiatric history, surgical vs natural menopause, age at onset. The entry's central tendencies (~4 year transition, ~75–80% VMS prevalence, ~2× depression risk, small cognitive dip) are reasonable defaults but each individual reader's experience will vary along these axes.

Knowledge gaps

Several gaps remain. (1) The mechanistic link between perimenopausal estradiol fluctuation and mood is biologically plausible and observed but not as cleanly mapped as the VMS pathway; whether estradiol-stabilisation therapies (e.g. transdermal estradiol patches in late perimenopause) prevent depressive episodes in high-risk women is still being evaluated. (2) Long-term cognitive trajectory after the transition is mostly reassuring (SWAN shows recovery) but whether subgroups exist who do not recover — and whether early MHT alters that trajectory — is not settled. (3) The contribution of perimenopausal vasomotor burden to long-term cardiovascular risk is suggestive (Thurston SWAN data) but not yet at the level of guideline action. (4) Best biomarker for staging late perimenopause beyond bleeding pattern (AMH, INSL3, transvaginal antral follicle count) — useful in research, not yet standard of care.

Scope and the brief. The brief named cycles, sleep, mood, cognition, body composition, and vasomotor symptoms. All six are covered as the six-domain map in the evidence section. The entry is framed as a recognition entry (action: know); downstream treatment specifics are deliberately out of scope to avoid blurring the literacy job with hormone-therapy prescribing, which warrants its own entry.

Hard scoping calls.

No protocol section. A literacy entry has no protocol to give. The closest thing — "raise it with your doctor, get a bleeding-pattern history, treat by symptom" — is woven through payoff rather than given its own section, because pulling it into a protocol would imply a do-this-now action the entry isn't actually authorising.
No contraindications section. The recognition act has no contraindications. Treatment contraindications belong with the treatment entries.
Genitourinary syndrome of menopause (GSM) is mentioned but not given its own subsection in the symptom map, because it's progressive rather than transition-bounded and deserves a standalone entry. It appears in stakes and payoff where it's load-bearing.

Separate-entry candidates flagged for the backlog.

Menopausal hormone therapy (formulations, candidate selection, timing hypothesis, contraindications).
Non-hormonal vasomotor treatment (SSRIs, gabapentin, fezolinetant).
Genitourinary syndrome of menopause as its own treatable condition.
Bone density screening cadence in midlife women (DXA timing, T-score thresholds, FRAX).
Premature ovarian insufficiency (menopause before 40).
Obstructive sleep apnea in midlife women specifically — different presentation and lower awareness than the male-coded sleep-apnea entry.

Rating difficulties.

longevity: 2 was the hardest call. The bone-loss window and cardiovascular trajectory are real and consequential, but the literacy substance itself doesn't change mortality — downstream interventions do. A 2 ("small additive") felt honest; a 3 would have implicitly claimed credit for treatments scored on their own entries.
focus: 2 reflects the SWAN cognitive dip's modest effect size (0.1-0.2 SD) and its recovery in postmenopause. Tempting to score higher because brain fog dominates lived-experience reports, but the actual measured dip is small and the score has to reflect the substance honestly.
cost_burden: 0 and effort_burden: 1 reflect the literacy entry specifically — recognising the pattern is free and light. The downstream treatments carry real burden and will be scored where they live.

Audience scoping. Set to female / 40-59. Excluding 18-39 because the entry's substance is normal-onset perimenopause; premature ovarian insufficiency is flagged separately. Late-30s onset exists but is rare enough that scoping to 40-59 reflects the actual primary audience without misleading. 60+ excluded because that population is postmenopausal, not in transition — though they may read for retrospective recognition.

Future link candidates. Once the entries above exist, wire cross-links from the symptom map into each.